Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a $26 price target.
July 22, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals and maintained a $26 price target.
The reiteration of a Buy rating and the maintenance of a $26 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100